CRISPR Therapeutics AG - Common Stock (CRSP)

485 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q1 2025.
CRISPR Therapeutics AG - Common Stock (CRSP) has 386 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 64.1M shares of 86M outstanding shares and own 74.59% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (10.2M shares), Capital International Investors (6.07M shares), T. Rowe Price Investment Management, Inc. (3.8M shares), BlackRock, Inc. (2.61M shares), Sumitomo Mitsui Trust Group, Inc. (2.54M shares), Nikko Asset Management Americas, Inc. (2.54M shares), STATE STREET CORP (2.41M shares), UBS Group AG (2.07M shares), UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC (1.95M shares), and FMR LLC (1.94M shares).
This table shows the top 386 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.